The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during ...

Bayer AG said an experimental stroke-prevention drug showed positive results in a late-stage study, a boost for the German ...

With sluggish pharmaceutical sales in the third quarter coming in below analysts’ expectations, Bayer is acutely aware of the challenges facing its key unit. | Despite the largely stagnant performance ...

The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.